Novick Diego, Montgomery William, Treuer Tamas, Moneta Maria Victoria, Haro Josep Maria
Eli Lilly and Company, Windlesham, Surrey, UK.
Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia.
Neuropsychiatr Dis Treat. 2016 Nov 14;12:2927-2939. doi: 10.2147/NDT.S101151. eCollection 2016.
This study explores sex differences in the outcomes of patients with schizophrenia (clinical/functional remission and recovery) across diverse regions of the world (Northern Europe, Southern Europe, Central and Eastern Europe, Latin America, East Asia, and North Africa and the Middle East). Data (n=16,380 for this post hoc analysis) were taken from the World-Schizophrenia Health Outcomes Study. In most regions, females had a later age at first service contact for schizophrenia, a lower level of overall/negative symptom severity, lower rates of alcohol/substance abuse and paid employment, and higher percentages of having a spouse/partner and independent living. Overall, females had slightly higher rates of clinical remission (58.0% vs 51.8%), functional remission (22.8% vs 16.0%), and recovery (16.5% vs 16.0%) at 36 months (<0.001 for all). This pattern was consistently observed in Southern Europe and Northern Europe even after controlling for baseline sex differences, but not in other regions. In Central and Eastern Europe, rates of clinical remission were higher in females at 36 months, but those of functional remission and recovery were similar between males and females. The opposite was observed for Latin America. In East Asia, sex differences were rarely observed for these outcomes. Finally, in North Africa and the Middle East, sex differences in these outcomes were pronounced only in regression analyses. These regional variations shed light on the importance of psychosocial and cultural factors and their effects on sex in the prognosis of schizophrenia.
本研究探讨了世界各地不同地区(北欧、南欧、中东欧、拉丁美洲、东亚以及北非和中东)精神分裂症患者(临床/功能缓解和康复)的结局中的性别差异。数据(本次事后分析为n = 16380)取自世界精神分裂症健康结局研究。在大多数地区,女性首次因精神分裂症接受服务的年龄较晚,总体/阴性症状严重程度较低,酒精/物质滥用和有偿就业的比例较低,有配偶/伴侣和独立生活的比例较高。总体而言,女性在36个月时的临床缓解率(58.0%对51.8%)、功能缓解率(22.8%对16.0%)和康复率(16.5%对16.0%)略高(所有均P<0.001)。即使在控制了基线性别差异后这种模式在南欧和北欧仍持续存在,但在其他地区并非如此。在中东欧,女性在36个月时的临床缓解率较高,但功能缓解率和康复率在男性和女性之间相似。在拉丁美洲观察到相反的情况。在东亚,这些结局很少观察到性别差异。最后,在北非和中东,这些结局的性别差异仅在回归分析中较为明显。这些地区差异揭示了社会心理和文化因素及其对精神分裂症预后中性别影响的重要性。